Finland's social insurance institution. It reimburses prescription medicines bought at pharmacies at 40%, 65% or 100%, and caps what a person pays for reimbursable medicines at EUR 636.12 in 2026.
Kela reimburses the cost of medicines, clinical nutrition products and emollient creams prescribed to treat an illness. A person pays the full price until an initial deductible of EUR 70.33 a calendar year; after that the basic rate of reimbursement is 40% of the sales or reference price, the lower special rate 65% and the higher special rate 100%, with a copayment of EUR 4.50 for each purchase at the 100% rate. Special rates need a right to reimbursement granted by Kela.
The annual maximum on out-of-pocket costs for reimbursable medicines, which includes the initial deductible, is EUR 636.12 in 2026. Beyond it a person pays a copayment of EUR 2.50 for each prescription medicine for the rest of the year, plus any amount above the reference price if they decline a cheaper substitute. Kela can lend the annual maximum to people on low incomes. The coordinates are an approximate Helsinki city point.
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-11-19.
Matched to Social Insurance Institution, including child institutions. 1 works · 0 citations · 100% open access · 0% clinical trials · 0% reviews.
| Work | Journal | Year | Citations |
|---|---|---|---|
| Risk factors of inability to live independently in the course of lung cancer 10.2478/ahem-2022-0050 · open access | Postępy Higieny i Medycyny Doświadczalnej | 2022 | 0 |
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/